索 引 号 bm56000001/2017-00005754 分 类 预先披露;预先披露 哈尔滨三联药业股份有限公司首次公开发行股票并上市招股说明书 （申报稿 2017年4月17日报送） 根据《证券法》第二十一条和《首次公开发行股票并上市管理办法》第五十八条、《首次公开发行股票并在创业 板上市管理办法》第四十条的规定，申请文件受理后、发行审核委员会审核前，发行人应当将招股说明书（申报稿） 在中国证监会网站预先披露。 发布机构 证监会 发文日期 【打印】 【关闭窗口】 名 称 哈尔滨三联药业股份有限公司首次公开发行股票并上市招股说明书（申报稿 2017年4月17日 报送） 文 号 主 题 词 ...

证券代码：002900 证券简称：哈三联 哈尔滨三联药业股份有限公司 投资者关系活动记录表 编号：2020-001 | --- | --- | --- | |----------------|--------------------------|------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | 现场参观 | | | | | 其他（深交所、黑龙江证监局、黑龙江省金融局联合举办 | | | | "东北资本市场服务周——走进哈三联"活动） | | | 1 、通过江海证券报名的 | 10 余名投资者； | | 参与单位名称及 | 2 、全景网记者 3 | 人； | | 人员姓名 | 3 、深交所投资者教育中心 | 2 人。 | | 时间 | 2020 年 11 月 10 | 日 9:30-12:00 | | 地点 | | 哈尔滨市利民开发区北京路哈尔滨三联药业股份有限公司 | ...

编号：2022-001 证券代码：002900 证券简称：哈三联 哈尔滨三联药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | 业绩说明会 | | 投资者关系活 动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | | | 参与单位名称 及人员姓名 | 参与"黑龙江辖区上市公司 说明会"的全体投资者 | 2022 年投资者网上集体接待日暨业绩 | | 时间 | 2022 年 5 月 12 日 | 14:30-16:30 | | 地点 | （ | 全景网"投资者关系互动平台" https ...

哈尔滨三联药业股份有限公司 2022 年第三季度报告 证券代码：002900 证券简称：哈三联 公告编号：2022-071 哈尔滨三联药业股份有限公司 哈尔滨三联药业股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 257,147,319.28 | 9.97% | ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥504.74 million, representing a 6.52% increase compared to ¥473.83 million in the same period last year[20]. - The net profit attributable to shareholders of the listed company was approximately ¥20.51 million, a significant decrease of 96.50% from ¥586.29 million in the previous year[20]. - The net profit after deducting non-recurring gains and losses was approximately ¥8.30 million, an increase of 127.41% compared to a loss of ¥30.29 million in the same period last year[20]. - The net cash flow from operating activities was approximately ¥30.56 million, a substantial increase of 261.31% from a negative cash flow of ¥18.95 million in the previous year[20]. - The total assets at the end of the reporting period were approximately ¥3.17 billion, reflecting a 3.52% increase from ¥3.07 billion at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company decreased by 3.74% to approximately ¥2.02 billion from ¥2.10 billion at the end of the previous year[20]. - The basic earnings per share were ¥0.07, down 96.30% from ¥1.89 in the same period last year[20]. - The diluted earnings per share were also ¥0.07, reflecting the same percentage decrease of 96.30% compared to the previous year[20]. - The weighted average return on net assets was 0.97%, a decrease of 27.37% from 28.34% in the previous year[20]. Revenue and Growth - The company reported a total non-operating income of CNY 12,202,138.53, primarily driven by government subsidies and fair value changes from trading financial assets[24]. - The company received government subsidies amounting to CNY 4,588,872.21 during the reporting period, which were recognized as income[24]. - The fair value changes from trading financial assets, particularly from investments in Hong Kong stocks, contributed CNY 9,571,985.02 to the income[24]. - The pharmaceutical sector accounted for 98.04% of total revenue, with a year-on-year growth of 9.64%[44]. - The solid preparation segment saw a revenue increase of 38.39%, primarily due to higher sales of Mianserin tablets[46]. - The company experienced a 190.01% increase in revenue from import and export trade, contributing significantly to overall growth[44]. Research and Development - The R&D team consists of 285 personnel, accounting for approximately 16.24% of the total workforce, focusing on innovative drug development and consistency evaluation projects[37]. - The company has developed a rich product line covering multiple therapeutic areas, including neurological, cardiovascular, and oncology diseases, enhancing its competitive advantage in brand and quality[35]. - The company is committed to enhancing its research and development capabilities to innovate and improve its product offerings[174]. Market Strategy and Expansion - The company plans to expand its market presence by entering three new provinces by the end of 2022[97]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[97]. - A new marketing strategy focusing on digital channels is set to be implemented, aiming for a 20% increase in online sales[97]. - The company is focusing on reducing operational costs by 10% through various efficiency measures and process optimizations[100]. Environmental and Compliance - The company has established facilities for hazardous waste storage and signed a contract for the disposal of hazardous waste with Heilongjiang Jingshenghua Environmental Technology Co., Ltd.[92]. - The company’s wastewater treatment facilities ensure that pharmaceutical wastewater is treated to meet standards before being discharged to the local sewage treatment plant[92]. - The company has implemented measures to reduce carbon emissions, although specific details were not provided[93]. - There were no administrative penalties received due to environmental issues during the reporting period[93]. - The company has developed an emergency response plan for environmental incidents, which has been filed with the local environmental protection bureau[93]. Shareholder and Governance - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its stock listing[96]. - Major shareholders are restricted from reducing their holdings within 12 months of the stock listing, with a price reduction not below the issuance price[96]. - The company ensures that any share transfers comply with the Shenzhen Stock Exchange rules and relevant regulations[96]. - The company has established a clear framework for shareholding commitments to maintain market stability[96]. Future Outlook - Future guidance estimates a revenue growth of 10-15% for the next fiscal year[97]. - The company plans to continue expanding its market presence and investing in new product development to drive future revenue growth[174]. - The company is committed to ongoing research and development efforts to innovate and introduce new technologies in its product offerings[126].

证券代码：002900 证券简称：哈三联 公告编号：2022-033 哈尔滨三联药业股份有限公司 关于举行 2021 年年度报告网上业绩说明会暨参加黑龙江省上市 公司投资者集体接待日活动通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为加强与广大投资者沟通交流，促进上市公司规范运作、健康发展，哈尔滨 三联药业股份有限公司（以下简称"公司"）将于 2022 年 5 月 12 日（周四） 14:30-16:30 举行 2021 年年度报告网上业绩说明会暨参加黑龙江省上市公司投资 者集体接待日活动，本次活动由黑龙江省上市公司协会联合深圳市全景网络有限 公司共同举办，公司将通过"全景路演"网上平台召开进行，投资者可登录"全景 路演"（https://rs.p5w.net/html/132395.shtml）参与在线交流。公司相关人员将与 投资者就公司治理，经营状况、发展战略、投资者保护等问题进行沟通。 出席本次年度网上业绩说明会的人员：公司董事长兼总裁秦剑飞先生，独立 董事曾国林先生，董事、副总裁兼董事会秘书赵庆福先生，董事、副总裁梁延飞 先生，财务总监赵 ...

Financial Performance - The company's operating revenue for 2021 was ¥945,799,422.97, a decrease of 29.36% compared to ¥1,338,882,990.74 in 2020[20]. - The net profit attributable to shareholders in 2021 was ¥350,951,064.21, a significant increase of 1,096.77% from ¥29,324,801.54 in 2020[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥148,479,133.39, reflecting a decline of 601.82% compared to -¥21,156,331.68 in 2020[20]. - The company's total assets increased by 23.47% to ¥3,065,517,046.80 at the end of 2021, up from ¥2,482,760,796.58 at the end of 2020[20]. - The basic earnings per share for 2021 was ¥1.13, representing a growth of 1,155.56% from ¥0.09 in 2020[20]. - The weighted average return on net assets was 18.11% in 2021, an increase of 16.48 percentage points from 1.63% in 2020[20]. - The net cash flow from operating activities was -¥12,533,851.80 in 2021, worsening by 178.09% from -¥4,507,046.05 in 2020[20]. - The company reported a total of ¥499,430,197.60 in non-recurring gains in 2021, compared to ¥50,481,133.22 in 2020[26]. - The total operating revenue for 2021 was approximately ¥945.8 million, a decrease of 29.36% compared to ¥1.34 billion in 2020[48]. - The pharmaceutical sector accounted for 95.14% of total revenue, generating ¥899.8 million, down 21.47% from the previous year[48]. Dividends and Share Capital - The company reported a cash dividend of 3.20 RMB per 10 shares (including tax) based on a total share base of 309,784,867 shares after repurchase[4]. - The company has a total share capital of 316,600,050 shares, with 6,815,183 shares repurchased[4]. - The company implemented a cash dividend policy, distributing a total of 99,131,157.44 CNY (including tax), which accounted for 100% of the total profit distribution[167]. - The cash dividend per 10 shares was set at 3.2 CNY (including tax), based on a total share capital of 316,600,050 shares, after deducting repurchased shares[168]. Business Operations and Strategy - The company has not changed its main business since its listing, indicating stability in operations[18]. - The company operates several wholly-owned subsidiaries, enhancing its market presence and operational capabilities[11]. - The company is actively involved in the development of innovative products and manufacturing upgrades to meet the evolving market demands[29]. - The company has a diverse product line covering various therapeutic areas, including neurological, cardiovascular, and anti-tumor diseases, which supports its vertical integration strategy[35]. - The company is focusing on developing new business lines, including animal drugs and health products, to create new profit growth points[46]. - The company has established a nationwide marketing system to adapt to intensified competition due to ongoing pharmaceutical reforms and policies[115]. - The company aims to enhance operational efficiency by focusing on projects with quicker returns amid industry challenges[96]. Research and Development - The company invested CNY 99.92 million in R&D during the reporting period, focusing on overcoming technical challenges and advancing projects like the consistency evaluation of generic drugs[41]. - The company employs 290 R&D personnel, accounting for approximately 19.09% of its total workforce, emphasizing its commitment to innovation and technology[37]. - Three products, including Ammonium Bromide Injection and Ondansetron Injection, successfully passed the consistency evaluation, enhancing the company's market position[41]. - New products such as the sodium omeprazole injection and the sodium chloride injection have been submitted for market approval, expected to create new growth points[65]. Market and Industry Trends - The pharmaceutical industry in China is experiencing a strong demand due to factors such as an aging population and increased healthcare awareness, with a long-term growth trend expected[28]. - The government aims for an average annual growth rate of over 8% in revenue and profit for the pharmaceutical industry over the next five years, emphasizing innovation and international development[29]. - The national medical insurance catalog was updated in December 2021, indicating a more scientific and standardized approach to drug inclusion[28]. Risk Management - The company faces risks including industry policy risks, drug research and development risks, and fluctuations in raw material prices[4]. - The company is actively managing risks related to raw material price fluctuations and supply interruptions by monitoring market trends and securing procurement agreements[117]. Governance and Compliance - The company has established a robust internal audit system to effectively control risks and ensure compliance[131]. - The company has a comprehensive internal management and control system tailored to its development needs[138]. - The company has established independent financial accounting departments and maintains independent bank accounts, ensuring no interference from controlling shareholders in financial decisions[136]. - The company has conducted 6 shareholder meetings during the reporting period, ensuring compliance with governance regulations[124]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with specific emissions data reported for various pollutants[179]. - The total emissions of sulfur dioxide were reported at 11,377.4 kg, within the regulatory limit of 49,280 kg[179]. - The company has implemented measures to ensure compliance with environmental standards, with no instances of exceeding discharge limits reported[179]. - The company has invested over 10 million yuan in environmental protection since its establishment, with 1.39 million yuan spent in 2021 for pollution detection and maintenance of environmental facilities[196]. Employee Management - The total number of employees at the end of the reporting period was 1,519, with 1,156 in the parent company and 363 in major subsidiaries[161]. - The employee training program included systematic internal training and external training to enhance technical skills and management capabilities[164]. - The company maintained a competitive salary policy, with fixed salaries ensuring stable income and performance-based incentives to motivate employees[162]. - The total number of technical personnel was 658, highlighting a strong emphasis on technical expertise within the workforce[161].

哈尔滨三联药业股份有限公司 2022 年第一季度报告全文 证券代码：002900 证券简称：哈三联 公告编号：2022-030 哈尔滨三联药业股份有限公司 2022 年第一季度报告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 256,694,410.27 | 230,179,061.88 | 11.52% | | 归属于上市公司股东的净利润（元） | -1,170,560.94 | 563,29 ...

哈尔滨三联药业股份有限公司 2021 年第三季度报告 证券代码：002900 证券简称：哈三联 公告编号：2021-079 哈尔滨三联药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增减 | 年初至报告期末 | 年初至报告期末比上年 同期增减 | | --- | --- | --- | --- | --- | | 营业收入（元） | 233,828,492.90 | -31.08% | 707,663,354.04 | -26.78% | | 归属于上市公司股东的 净利润（元） | -46,541,203.45 | -682.09% | 539,750,248.11 | 2,335.69% | | 归属于上市公司股东的 扣除非经常性损益的净 | -11,230,959.21 | -108.76% | -41,525,850.86 | -92. ...

哈尔滨三联药业股份有限公司 2021 年半年度报告全文 2021 年半年度报告 哈尔滨三联药业股份有限公司 2021-069 2021 年 08 月 1 哈尔滨三联药业股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人秦剑飞、主管会计工作负责人赵志成及会计机构负责人(会计主 管人员)翟明卉声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能面临行业政策风险、新药研发风险、原材料价格波动及供应中断 风险、募投项目不达预期的风险、风险投资收益波动的风险等，详细内容已在 本报告第三节"管理层讨论与分析（十）、公司面临的风险和应对措施"部分予 以描述。敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | | 2 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 ...